The rating by the firm was issued on June 8, 2016. During the last trade, shares reached to high price of $1.05 and touched the low price of $1.00. According to the latest information available, the shares are now rated Buy by the analysts at the agency. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $170.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, February 25th.
Advertisement
Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its quarterly earnings results on Tuesday, June 7th. That brought the Valeant Pharmaceuticals stock closing price to $24.14. Major Brokerage house, Jefferies maintains its ratings on Valeant Pharmaceuticals International (NYSE:VRX). Finally, Nebula Capital Management LP boosted its stake in Valeant Pharmaceuticals Intl by 264.0% in the fourth quarter. Rodman & Renshaw assumed coverage on Valeant Pharmaceuticals Intl in a research note on Tuesday, February 16th.
The share price fell 36 cents or 1.49 per cent to US$23.78 on Monday. When considering if perhaps the stock is under or overvalued, the average price target is $32.08 which is 32.9% above where the stock closed yesterday.
Out of the 22 analysts who provide coverage on Valeant stock, seven analysts believe that the investors should place a long position in the stock. The 52-week high of the share price is $263.81 and the 52-week low is $22.52. The company has a market cap of $8.11 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
But since September 2015 it has suffered a series of injuries to its reputation: The company has been dragged in front of US lawmakers for buying drugs and subsequently jacking up prices; it has been accused of operating “phantom pharmacies”; and then Pearson resigned, with the company placing most of the blame for incorrect financial reporting on its former chief financial officer (and, briefly, acting chief executive) Howard Schiller. The firm had revenue of $2.37 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter past year, the company posted $2.36 earnings per share. Out of all the polled analysts, the most bullish estimate has the stock hitting N/A in the next year.
Several Insider Transactions has been reported to the SEC.
Among the seven of 14 board members not seeking re-election are former CEO Michael Pearson and former chief financial officer Howard Schiller, as well as five independent directors.
Things might finally be calming down with Valeant Pharmaceuticals International Inc. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries.
Advertisement
In the Emerging Markets segment, revenues increased $15 million, primarily from the acquisition of Amoun Pharmaceutical Company S.A.E. of $59 million, partially offset by a negative foreign currency exchange impact.
